WEI-WU CHENKOPING CHANGCHIA-LANG HSUJEN-CHIEH LEEChen, San-ChiSan-ChiChenRUEY-LONG HONGCHIH-WEI YUChen, Mei-LuMei-LuChenHsu, Meng-ChiMeng-ChiHsuKung, Ting-FangTing-FangKungJHE-CYUAN GUOYen, Chueh-ChuanChueh-ChuanYenANN-LII CHENG2023-01-102023-01-102022-12-011078-0432https://scholars.lib.ntu.edu.tw/handle/123456789/627088Satisfactory treatment options for advanced leiomyosarcoma and liposarcoma are limited. The LEADER study (NCT03526679) investigated the safety and efficacy of lenvatinib plus eribulin.enB-CELLS; BEVACIZUMAB; CHEMOTHERAPY; COMPLEMENT; PAZOPANIB; SURVIVAL; TRIALS[SDGs]SDG3journal article10.1158/1078-0432.CCR-22-2092361294712-s2.0-85143180013WOS:000893071000001https://api.elsevier.com/content/abstract/scopus_id/85143180013